v3.24.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Common Stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total
Beginning balance at Dec. 31, 2020 $ 1 $ 585,374   $ (488,195) $ 97,180
Beginning balance, shares at Dec. 31, 2020 [1] 56,890,569        
Net income       34,597 34,597
Issuance of common stock   29,700     29,700
Issuance of common stock, Shares [1] 1,270,462        
Exercise of options   9,371     9,371
Exercise of options , Shares [1] 664,738        
Stock-based compensation   15,659     15,659
Ending balance at Dec. 31, 2021 $ 1 640,104   (453,598) 186,507
Ending balance, shares at Dec. 31, 2021 [1] 58,825,769        
Net income       181,468 181,468
Unrealized gain (loss) on investments     $ (151)   (151)
Issuance of common stock   408     408
Issuance of common stock, Shares [1] 8,050        
Exercise of options   8,433     8,433
Exercise of options , Shares [1] 781,912        
Stock-based compensation   26,173     26,173
Ending balance at Dec. 31, 2022 $ 1 675,118 (151) (272,130) 402,838
Ending balance, shares at Dec. 31, 2022 [1] 59,615,731        
Net income       128,853 128,853
Unrealized gain (loss) on investments     153   153
Repurchase of common stock   (101,097)     $ (101,097)
Repurchase of common stock, Shares [1] (3,254,445)        
Exercise of options , Shares         371,896
Exercise of options and vesting of restricted stock units [2]   4,540     $ 4,540
Exercise of options and vesting of restricted stock units, Shares [1],[2] 407,795        
Stock-based compensation   31,705     31,705
Ending balance at Dec. 31, 2023 $ 1 $ 610,266 $ 2 $ (143,277) $ 466,992
Ending balance, shares at Dec. 31, 2023 [1] 56,769,081        
[1] Common stock of Harmony Biosciences Holdings, Inc.
[2] Inclusive of fees and 1% excise tax on shares repurchased.